Phosphagenics - Investors Announcements

Company Overview

Board

Corporate Governance

Financial Reports

Presentations

Company Announcements

AIM

Shareholder Information

-	Share Price Information
-	Investor Downloads
-	Investor Contacts

Company Announcements

2008

12 November 2008 - Transdermal diclofenac enters phase 1 clinical trial in humans

05 November 2008 - Metabolic Syndrome Phase 2 Clinical Trial Recruitment Completed

07 October 2008 - Phosphagenics presentation at the annual pail therapeutics summit 2008

03 October 2008 - Appendix 3Y

23 September 2008 - Phosphagenics announces initiation of Phase 1 clinical trial in humans for its transdermal lidocaine

22 September 2008 - AIM update

19 September 2008 - Initial substantial shareholder notice

29 August 2008 - Half Yearly Report and Accounts for the period ended 30 June 2008

21 July 2008 - Phosphagenics July Newsletter

8 July 2008 - Appointment of Director, appendix 3X

8 July 2008 - Phosphagenics appoints US based non-executive director

11 June 2008 - Form 605 (cessation of substantial shareholding)

26 May 2008 - Final Directors Interest Notice

23 May 2008 - Annual General Meeting Results

23 May 2008 - Annual General Meeting - Chairman and CEO's address

22 May 2008 - Change of Directors Interest Notice

20 May 2008 - Appendix 3B

20 May 2008 - Phosphagenics' executive appointment

13 May 2008 - Change in substantial holding

07 May 2008 - Phosphagenics completes A$9.1m Capital Raising

05 May 2008 - Trading Halt

30 April 2008 - Phosphagenics reports positive pre-clinical results for targeted delivery of lidocaine

21 April 2008 - Excellence in Biotechnology Investment Conference presentation

14 April 2008 - 2007 Annual Report and AGM documentation

19 March 2008 - Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes

18 March 2008 - GRAS status opens door to U.S. food industry

13 March 2008 - Change of Directors Interest Notice

05 March 2008 - Change of Directors Interest Notice

27 February 2008 - Phosphagenics 2007 Financial Report/Appendix 4E

19 February 2008 - Phosphagenics initiates US clinical trials for its topical retinoic acid

11 February 2008 - Progression of Phosphagenics and NESTLÉ Nutrition's Phospha E trial

30 January 2008 - Phosphagenics reports superior pre-clinical cholesterol results from APA-01 and atorvastatin combination

2007

17 December 2007 - Successful transdermal oxycodone clinical trial results

10 December 2007 - Change of Directors interest notice

04 December 2007 - Phosphagenics' presentation: BBY 2007 Healthcare & Life Sciences Conference

03 December 2007 - December 2007 Newsletter and Annual Report Retention Notice

27 November 2007 - Notice of change of interests of substantial holder

08 November 2007 - Change of Directors interest notice

19 October 2007 - Dietary supplement update

04 October 2007 - NESTLÉ Nutrition and Phosphagenics to commence Phospha E® Phase 2 clinical trial

28 September 2007 - Change of Directors interest notice

25 September 2007 - Change of Directors interest notice

24 September 2007 - Phase 1 transdermal oxycodone clinical trial approved

17 September 2007 - Phosphagenics to conduct a Phase 1 transdermal oxycodone clinical trial

12 September 2007 - Phosphagenics to commence Phase 2 TPM/Insulin clinical trial

30 August 2007 - Half Yearly Report and Accounts for the period ended 30 June 2007

21 August 2007 - Appendix 3B exercise of options

08 August 2007 - Positive Phase 1b transdermal insulin clinical trial results

02 August 2007 - Appendix 3B

10 July 2007 - Phosphagenics lists on the International OTCQX market in the US

09 July 2007 - Phosphagenics and NESTLÉ extend option agreement

04 July 2007 - Phosphagenics information to be available through S&P Corporate Records Listing Program

21 June 2007 - Phosphagenics dermal delivery breakthrough

04 June 2007 - Phosphagenics awarded a $2.1 million AusIndustry Grant

31 May 2007 - Change in substantial holding and change of Directors interest notice

25 May 2007 - Annual General Meeting results

25 May 2007 - Annual General Meeting - Chairman's Address

22 May 2007 - Phase 1b insulin clinical trial commenced

03 May 2007 - AusIndustry offers Phosphagenics a Pharmaceuticals Partnerships Program (P3) grant of $3.2 million

01 May 2007 - Phosphagenics to commence insulin clinical trial in May

27 April 2007 - Change of Directors interest notice

24 April 2007 - 2006 Annual Report & AGM documentation

15 March 2007 - Phosphagenics' presentation: Cowen and Company 27th Annual Health Care Conference

15 March 2007 - Change of Directors interest notice

14 March 2007 - Phosphagenics to present at Cowen and Company 27th Annual Health Care Conference

07 March 2007 - Phosphagenics extends transdermal technology platform

23 February 2007 - Phosphagenics 2006 Financial Yearly Report/Appendix 4E

07 February 2007 - Change in substantial holding x 2

29 January 2007 - Appendix 3B

18 January 2007 - NESTLÉ Phospha E option agreement details

12 January 2007 - NESTLÉ enters commercial discussions with Phosphagenics

Web Site Design & Business Hosting by Simple I.D.